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ABSTRACT 
The present research advances the area of targeted radionuclide therapy (TRT) by 
using nanoparticles as intrinsic carriers of radionuclides. In here we proposed the use of 
nuclear nanotechnologies where nanoparticle cores serve as super-carriers of 
radionuclides, potentially yielding new endo-radiotherapy agents with a higher safety 
and efficacy profile than those currently used in TRT.  We studied a new original 
concept in TRT by introducing radioactive gold nanoparticles as carriers of the 
therapeutic payload while increasing the number of radioactive atoms per tumor cell. By 
separating the radionuclide from the targeting agent, it was possible to avoid the severe 
effects of radiolysis in molecular decomposition of the targeting agent, which is 
currently a limiting factor in TRT. We studied under this paradigm the beta-particle 
emitter 
198
Au (t1/2 = 2.69 d).
Using radioactive gold Au-198 (t1/2 = 2.69 d) as a therapeutic load and the 
cationic cell penetrating peptide (CPP) HIV-1 Tat as a targeting agent, we developed the 
198
Au-AuNP HIV-1 Tat as a therapeutic strategy for the treatment of breast cancer 
metastases. The breast cancer cell line SKBr-3 was used to test the cytotoxicity of 
198
Au-
AuNP HIV-1 Tat with different activity concentrations for an incubation time of 12 
hours. The Real Time Cell Analyzer (RTCA) was used to quantitate the cell growth or 
delay as a function of time. When compared to controls, a delay in cell growth was 
observed for wells that were administered an activity of 1000 and 1500 kBq whereas no 
significant changes were observed for 50, 100 and 500 kBq. The effect of functionalized 
iii 
198
AuNP-HIV1-Tat was observed to have a small effect in cell growth when compared 
with 
198
AuNP alone.
Moreover, cell growth delay was compared with that obtained using external 
beam radiation therapy (2 Gy) and the chemotherapy agent doxorubicin. Results 
indicated that 
198
Au-AuNP HIV-1 Tat at 5000 kBq was similar in toxicity to external
beam therapy and lower than doxorubicin. We predict the use of cell penetrating 
peptides in combination with intrinsically radioactive nanoparticles as a new strategy 
against metastatic breast cancer. 
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1. INTRODUCTION 
 
1.1 Cancer Statistics 
Cancer is a significant problem worldwide. A report by the World Health 
Organization (WHO) indicates that cancer will become, or already is, a global problem 
affecting third world countries disproportionately (1). As life expectancy increases 
around the world, the incidence of cancer continues to climb and it is expected to be the 
number one cause of death surpassing cardiovascular disease. It is estimated that there 
will be more than 25 million new cancer cases worldwide each year after the year 2025. 
Thus, cancer prevention and the development of individualized target therapies strategies 
must be given priority in order to minimize its societal burden.  
According to SEER cancer statistics for the time period from 2005 to 2009, the 
average age at diagnosis for all type of cancers was 66 years. The age-adjusted incidence 
rate from 2005 to 2009 was 465.2 per 100,000 men and women per year and the median 
age of death from all type of cancers was 72 years (2). The age-adjusted death rate based 
on SEER statistics was 178.7 per 100,000 men and women per year (2). 
 
1.2 The Prevalence of Cancer Metastases 
The ability for tumor to metastasize makes cancer a fatal disease. A majority of 
cancer related deaths in the US can be attributed to metastatic disease progression rather 
than the primary tumor. At the time of diagnosis of cancer, at least half of the patients 
already present clinically detectable metastases. When a primary tumor is formed, 
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malignant cells in the primary tumor will tend to dissociate or release from the primary 
tumor mass, at an unknown rate, and travel in the body via the circulatory or lymphatic 
systems until they settle in a distant organ to develop secondary tumors. Unfortunately, a 
large portion of patients may already have developed clinically undetectable metastases 
or micro-metastases by current radiological or pathological techniques, at the time of 
diagnosis. 
 
1.3 Current Therapies for Cancer 
Currently, there are multiple approaches for cancer treatment depending on stage 
and disease progression. Surgery is considered to be the oldest and most effective 
strategy for tumors in early stages. The second strategy is chemotherapy. Historically, 
chemotherapy was introduced after World War I when nitrogen mustard was used to 
treat cancer (3). Chemotherapy is typically considered to be systemic treatment. 
Chemotherapy agents can be administrated intravenously or orally and they are 
commonly used along with surgery, external radiation therapy, or biological therapy 
(adjuvant therapy). Chemotherapeutics target non-specifically rapidly dividing cells 
using different mechanisms of action, depending on what aspect of the cell cycle and 
division they affect. However, chemotherapy can harm and affect healthy cells that 
naturally divide quickly, such as the stomach and intestines, bone marrow, and hair 
follicles. Fortunately, most of the side effects disappear few months post-administration.  
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After the discovery of x-rays by William Roentgen in 1895 the concept of 
external beam radiotherapy was immediately proposed. Today, approximately two thirds 
of all cancer patients treated in modern facilities will receive some form of radiation 
therapy as part of the cancer management plan. External beam radiotherapy is a complex 
treatment strategy, since it is grounded on the radiobiology of normal and tumor tissues 
(4). This modality is very effective against primary solid tumors and it requires a clear 
definition of the confined volume of the target and dose prescription. External beam 
therapy treatment consists of multiple treatment sessions to minimize acute and delay 
side effects to normal tissues while limiting the dose prescription to the tumor mass; 
unfortunately, once cancer disseminates and metastasizes to other organs and tissues, 
external beam radiotherapy is ineffective.  
Brachytherapy is a modality that is similar to external beam radiation therapy, 
which uses sealed radioactive sources that are permanently implanted or localized 
temporarily within, or proximal to, a tumor tissue. The idea of using sealed sources to 
treat cancers was proposed initially by Pierre Curie, shortly after the discovery of 
radioactivity in 1896. This modality requires that the target tumor volume be well 
defined or the source be confined within a tissue. The sealed sources used in 
brachytherapy must generate a steep dose gradient in order to confine the dose to the 
tumor volume. The radioactive sources commonly used in brachytherapy are iodine-125 
(
125
I), cesium-137 (
137
Cs), cobalt-60 (
60
Co), Iridium-192 (
192
Ir), palladium-103 (
103
Pd), 
ruthenium-106 (
106
Ru). Brachytherapy is further divided according to source placement, 
intensity of dose rate, and total dose. Brachytherapy has been used effectively in treating 
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localized prostate, breast, skin, cervical, oral, soft tissue sarcomas, gynecological and 
other cervix, head and neck, and central nervous cancers.  
As with external beam radiotherapy, the use of brachytherapy can also induce 
deleterious side effects to normal tissues; therefore, careful treatment planning must be 
carried out in order to avoid severe side effects. Both external beam radiation therapy 
and brachytherapy require that the tumor be anatomical well confined within a region or 
organ and be geographically limited; however, when tumor progression occurs and a 
tumor disseminates beyond the primary site, such treatment modalities cannot be 
employed effectively. Therefore, other systemic treatment strategies, such as 
chemotherapy, must be used.  
Advances in understanding cancer biology, the immunological system, and the 
differential expression of cell surface receptors between cancer and normal cell types has 
allowed the advancement of a group of strategies known as ‘targeted therapies’ in the 
treatment of cancer using drugs that exploit these differences between normal and tumor 
cells. Paul Ehrlich originally suggested the concept of targeted therapy in the early 1900s 
(5), this approach has gained particular attention in the last 20 years, since the advent of 
the genomic revolution (6). Targeted therapies, including cancer immunotherapy, are 
historically rooted in principles of microbiology and immunology, and these two 
research areas today form the core basis for developing new biological anticancer agents 
(7). The development of these agents has come about by understanding the cascade of 
events, commonly referred as the “signal transduction cascade” (8, 9), that are triggered 
by cell surface receptors and other cell-to-cell communication mechanisms or pathways. 
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These events induce a cell to carry out a specific task, such as proliferation, invasion, or 
migration, by secreting proteins capable of, for example, degrading the extracellular 
matrix of normal tissues for invasion purposes or induction of angiogenesis (formation 
of new blood vessels). The obstruction or inhibition of these cellular processes by 
specific biological drugs has shown to be effective in certain type of cancers. These 
drugs affect or interfere with the cascade of signals that are transmitted once a receptor is 
activated at the surface of the cell. The most significant of these biological drugs has 
been the humanized monoclonal antibody (mAb) trastuzumab (Herceptin
®
) for the 
treatment of breast cancer. This humanized mAb blocks the human epidermal growth 
factor receptor 2 (HER2) that is involved in the signal cascade associated with cell 
proliferation, migration, and invasion (10). Other therapeutics directed against or 
targeted at inhibiting a specific cellular process or protein target (e.g., kinases) of 
relevance to tumor proliferation have also been developed (8). These drugs, referred to 
as inhibitors, often are small molecules compared to antibodies (11), some of which have 
shown considerable success in treating or controlling disease progression. 
 
1.4 Targeted Radionuclide Therapy (TRT) 
The employment of the combination of a high specificity immunotherapeutic 
agent with a radionuclide to effect targeted and localized killing of tumor cells, 
commonly referred as targeted radionuclide therapy (TRT) (5), has shown particular 
promise. The intent of radiation therapy is to use ionizing radiation to kill cancer cells by 
inducing cell death; in this manner it will stop these cells from growing and dividing. 
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One of the most applied methods that involve exposing patients to radiation is the 
external beam radiation therapy. This method uses multiple beams of high energy x-rays 
that irradiate a bounded area of the body, thereby concentrating the absorbed dose to the 
tumor tissue while minimizing the dose to normal surrounding tissues.  
On the other hand, TRT uses a molecule, such as a monoclonal antibody, that 
attaches to antigens or receptors that are either over-expressed or located only on the 
surface of tumor cells. This molecule is labeled with a radionuclide in order to deliver a 
toxic level of radiation to both localized and disseminated disease sites scattered around 
the body. Unlike tumor-directed drugs and toxins, which kill only the targeted cells, an 
attractive feature of radionuclides is that their radiative emissions (beta and alpha 
particles) can exert a “crossfire” effect, potentially destroying adjacent tumor cells even 
if they do not over-express the specific tumor-associated antigen or receptor. 
Furthermore, TRT has the exclusive potential to eliminate both tumor cells at the 
primary tumor site and tumor cells that have spread throughout the body (metastases), 
including malignant cell populations that are clinically undetectable by radiographic 
imaging (commonly referred to as minimal residual disease).  
Generally, the radio-therapeutic agent has two components: a radionuclide and a 
carrier that specifically attaches to tumor cells. Examples of molecular carriers are 
peptides, which seek and attach to their corresponding cell-surface receptors, and 
monoclonal antibodies, which attach to antigens that are expressed on the cell surface of 
tumor cells. The radionuclide that is attached to the carrier molecule can be chosen for 
its specific radiological characteristics, such as decay scheme, type of emitted radiation 
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(e.g., alpha, beta, or gamma emitter), radiation range in tissue, and physical half-life. It is 
this modularity, where the components can be varied like interlocking building blocks, 
which allows the matching of the spatiotemporal pathophysiology specific of a tumor.  
This strategy has been studied considerably for the last two decades. So far, the 
Food and Drug Administration has approved three TRT agents. The first two agents; 
namely, 
131
I-labeled tositumomab (BEXXAR
®
, GlaxoSmithKline) and 
90
Y-labeled 
ibritumomab tiuxetan (Zevalin
®
, Spectrum Pharmaceuticals, Inc.) were approved for the 
treatment of Non-Hodgkin’s lymphoma (NHL) in the year 2003 and 2002, respectively. 
A third TRT drug, 
223
RaCl (Alpharadin
®
), was recently submitted to the FDA for 
approval and it is prescribed for the treatment of bony metastases from castration 
resistant advanced prostate cancer (CRPC). The radionuclide 
223
Ra is an alpha particle 
emitter with a physical half-life of 11.435 days. The approval of these agents has 
considerably boosted the research area of targeted radionuclide therapy, specifically, 
radioimmunotherapy. Currently, there are more than one hundred clinical trials using 
radioimmunotherapy as a treatment strategy.  
Despite its advantages, TRT suffers from significant drawbacks. When a 
chemical or biological compound is radiolabeled, the “conjugate” (as it is commonly 
referred to) may dissociate due to ineffective chemical binding (ionic vs. covalent 
bonds), or it may become defective due to the high energy deposited by the radioactive 
substance into the sample (a process commonly referred as radiolysis). Therefore, only a 
fraction of the agent is labeled with a radionuclide and, in many instances, it is less than 
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5%. These are limitations that need to be resolved in order to enhance the effectiveness 
of TRT.  
There have been many failures in seeking new TRT strategies, specifically for 
solid tumors and minimal residual disease settings. Many antigens have been tested as 
targets, using intact monoclonal antibodies or fragments. Several such targets have been 
found to be of little value, due either to low receptor expression or to extensive shedding 
into the blood stream, which make it almost impossible to specifically target the tumor 
sites themselves. Shedding interferes with targeting efficiency because of the depletion 
of radioactively labeled antibodies by circulating antigens, with subsequent uptake and 
degradation by the reticuloendothelial system (RES; liver, spleen). For example, the 
carcinoembryonic antigen (CEA), which is over-expressed in in patients with colorectal 
carcinoma, gastric carcinoma, pancreatic carcinoma, lung carcinoma and breast 
carcinoma, as well as individuals with medullary thyroid carcinoma, appears in blood in 
soluble form, and its high levels in blood compromises the binding of TRT agents to 
tumor cells (12). On the other hand, the CD20 antigen, which is over-expressed in all B-
cell lymphomas, is an excellent target because it is neither shed in blood nor internalized 
by tumor cells (13).  
The current trend in the pharmaceutical industry is to develop new therapy 
strategies capable of modifying the pathophysiology of tumors and the pharmacokinetics 
and pharmacodynamics (PK/PD) of existing drugs. This is accomplished by combining 
therapies for different cellular targets and with different mechanisms of action, that 
affect the survival and cell division of tumor cells. A large body of clinical evidence 
9 
supports the use of combined modality approaches based on the combination of ionizing 
radiation with known therapeutic molecules. The additive and synergism resulting from 
the combination of radiation and cytotoxic drugs has been shown in many clinical cases 
(14). However, in many other instances, combination therapies utilizing radiotherapy fail 
to show an additive or synergistic response (15, 16). The fundamental cause for such 
failure seems to be that they are spatiotemporally mismatched, as both therapies do not 
present themselves simultaneously to individual tumor cells at the correct time window 
and above a specific threshold concentration level (therapeutic dose), and that similar to 
efficacy, this may result in potential additive or synergistic toxicities. Therefore, basic to 
the use of a combined multimodality treatment is an understanding of the individual 
spatiotemporal effects of radiation and drugs and their combined interaction. 
This area of combination therapy represents an important niche in translational 
cancer research. In order to address this niche, our labs are developing a new paradigm, 
referred to as nuclear nanotechnologies, that combines novel nanoparticles (e.g., gold, 
polymeric nanoparticles) with radioimmunotargeting strategies to create 
spatiotemporally matched combination therapies. 
1.5 Radioactive Nanoparticles in TRT 
In traditional targeted radionuclide therapy, one radioactive atom is attached to 
one targeting agent (i.e., monoclonal antibody). Typically, the efficiency (labeling yield) 
for radionuclide labeling is quite low, with labeling fractions ranging from 10
5
:1 to 10
3
:1
(unlabeled versus labeled antibody). However, a potential increase in efficacy can be 
10 
achieved by significantly increasing the payload per target agent. Our research is aimed 
at exploring the enhancement of therapeutic efficacy by the combination of 
immunotargeting and nuclear nanoparticle technologies. 
Radioactive nanoparticles can carry not only a radioactive payload but also a 
biological modifier and/or a cytotoxic drug that can be spatiotemporally offered 
‘simultaneously’ to each individual tumor cell. The use of nanocarriers transporting 
multiple payloads avoids issues of mismatched spatiotemporal effects, potentially 
inducing an additive or synergistic therapeutic effect to individual tumor cells. Although 
this is not a new concept, it is an approach that needs to be carefully studied at the in 
vitro and in vivo translational levels (17). 
Nanoparticle technologies offer many advantages in comparison to traditional 
drug design and delivery methods (18). Nanocarriers can impact cancer treatment by 
improving the general pharmacokinetic (PK) properties of drugs, by increasing their 
solubility, retention, and tumor bio-distribution, and by providing multi-functional 
capabilities. As a consequence, there is a significant reduction in toxicity and an increase 
in efficacy. A typical clinical example is the chemotherapy drug Doxil (doxorubicin HCl 
liposome injection). Doxorubicin is a powerful anthracycline antibiotic used as a 
chemotherapy agent that works by intercalating DNA. Doxorubicin (Doxil) alone 
produces severe cardiac toxicity; however, when formulated as a liposomal drug, its 
solubility increased considerably while cardiac toxicity was reduced significantly. Doxil 
has been, and continues to be, used as a drug model for other nanotherapeutics (19). 
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Despite the advantages of nanoparticles, radioactive nanoparticles research for 
cancer therapy has been limited. This is due to difficulties in producing radioactive 
nanoparticles using synthetic methods under tracer conditions or complications with 
stabilizing nanoparticles (20). As an example, the generation of 
198
Au nanoparticles 
(
198
AuNPs) under physiological conditions using nontoxic agents in the presence of a 
functionalizing biomolecule, such as a monoclonal antibody, is still a major challenge. 
The challenges for the generation of radioactive NPs include:  
a) Developing a method for the synthesis of radioactive NPs in isolation while 
avoiding NP aggregation.  
b) Stabilization of radioactive NPs in a desired functional form (such as 
PEGylation). 
c) Functionalization (i.e., immuno-conjugation) of an active targeting agent to 
the stabilized radioactive NPs while maintaining its immunological properties 
under extreme physiological conditions, such as those encountered in the 
tumor microenvironment. 
d) Prevention of an immunological response by the immune system and 
corresponding toxicity (21-24).  
 
1.6 Cell Penetrating Peptides 
The cell membrane is a biological barrier that encloses the cytoplasm of cells. 
This membrane act as a protection for the cell plasma that regulates what enters the cell 
depending on their molecular size. However, some of the drugs that are used for cancer 
12 
treatment are large enough to be blocked by the cell barrier. Therefore, an interesting 
method for the delivery of drugs of large molecules into the cell cytoplasm was 
discovered by the use cell penetrating peptides (CPP). 
CPPs are divided into subgroups: protein derived (P), chimeric (C), and 
designed/synthetic (S). The most recognized CPPs is the (P) subgroup that is entirely 
derived from naturally occurring proteins such as HIV-1 encoded Tat protein. The main 
difference between chimeric and the designed/synthetic group is that the parental 
sequence in the chimeric group are partially naturally occurring peptide whereas the 
designed or synthetic group are unnatural and designed in laboratories.  
The mechanism by which CPPs penetrate cells has not been fully elucidated. 
CPPs were discovered by Frankel and Pabo in 1988, who proved that that the 
transcription-transactivating (Tat) protein of HIV-1 can penetrate the cell membrane 
without causing significant damage (25).  The CPPs are of various amino acids 
sequences and sizes. Today, they are commonly used in the field of cancer especially for 
breast cancer treatment. For example, by conjugating CPPs with a chemotherapy agent 
for a breast cancer treatment, the delivery of the drugs will efficiently increase. Figure 1 
illustrate overview of applications for cell penetrating peptides (CPPs) for use in vitro 
and in vivo 
13 
Figure 1. Overview of applications for cell penetrating peptides (CPPs) for use in vitro 
and in vivo (26). CPPs can be used to introduce peptides, proteins, antibodies, small 
interfering RNA (siRNA), small molecular weight drugs, plasmids and DNA.   
1.7 Proposed Therapeutic Strategy 
The present research explores a new paradigm of targeted nuclear 
nanotechnologies using the approach of immuno-targeted delivery of radioactive (
198
Au)
gold nanoparticles for the treatment of breast cancer in the SKBr-3 cell line and the 
potential of this strategy for the treatment of disseminated disease. The present strategy 
utilizes 
198
Au as a cytotoxic agent embedded into a gold nanoparticle that is 
functionalized with a HIV-1 Tat CPP for its targeted delivery as illustrated in Figure 2. 
We have selected 
198
Au for its simple production; however, 
198
Au can be substituted for
other radionuclides with potentially more advantageous radiobiological properties such 
as the Auger emitting radionuclide 
125
I, or the alpha particle emitting radionuclide 
211
At.
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Figure 2. The proposed therapeutic strategy of functionalized 
198
AuNp with a HIV-1 Tat 
CPP  
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2. METHODS  
 
2.1 Cell Lines and Cell Culture 
The breast cancer cell line SKBr-3 (ATCC Catalog No. HTB-30
TM
) was obtained 
from American Type Tissue Culture (ATCC, Manassas, VA). This cell line was isolated 
and derived from the pleural effusion of a patient with breast adenocarcinoma at the 
Memorial Sloan-Kettering Cancer Center (MSKCC) in 1970. This cell over-expresses 
the HER2/c-erb-2 gene product producing an excessive number of HER2 receptors on 
the cell surface (25). The HER2 receptor has no natural ligand; however, a murine 
monoclonal antibody has been developed and humanized by Genentech, Inc. (27)  
Cell culture was carried out according to the ATCC product information sheet. 
Briefly, the base medium used was ATCC-formulated McCoy’s 5a Medium Modified 
(ATCC Catalog Number 30-2007) with 10% fetal bovine serum. No antibiotics were 
added to the growth medium. The SKBr-3 cell line was incubated in a 5% CO2 
atmosphere under sterile conditions. Sub-culturing and passage was carried out using 
175 cm
2
 flasks where the medium was removed and discarded and the cell layer was 
rinsed with the dissociating reagent TrypLE
TM
 Express (Gibco®, Life Technologies, 
Grand Island, NY) for a period of 15 minutes or until cells detached from the surface of 
the flask. Cells were then aspirated into a 50 mL conical tube and 1 mL of the cell 
suspension was used to continue the propagation of the cell line into another new flask 
with 30 mL of fresh media. The remaining cells were then collected by centrifugation 
and used for experiments. Cell centrifugation was carried out at 100×g (relative 
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centrifugal force) for 5 min. The supernatant was discarded and cells were re-suspended 
in 5 mL of fresh growth medium at 37 °C for use in further experiments.  
 
2.2 Real Time Cell Analysis (RTCA) 
A label-free real-time cell analyzer (RTCA) was used to assess cell growth and 
cell-mediated toxicity of cytotoxic agents to attached cells. The xCELLigence RTCA DP 
analyzer (ACEA Bioscience, Inc. San Diego, CA) uses impedance measurement to 
assess the real-time response of attached cells to x-ray radiation, chemotherapeutics, and 
198
AuNPs on SKBr-3 cells. The system has three plates and each plate has 16 wells that 
are continuously monitored by the system, providing a real time cell index response as a 
function of time. The cell index (CI) response has arbitrary units. Using experimental 
controls, the response of a cytotoxic agent can be estimated as a function of time. This 
system supersedes the use of the commonly used clonogenic assay (28), which only 
determines the potential for proliferation of cell in vivo as a function of absorbed dose or 
molar concentration. 
The RTCA system requires the estimation of an optimal number of cells for 
seeding (per well) as to allow such cells to proliferate for a period time before treatment 
with a cytotoxic agent. In order to assess the optimal seeding per well, an initial 
experiment was carried out using various seeding numbers (3300, 5500, 10000, and 
25000 cells per well). Once the optimal seeding number is established for SKBr-3, future 
experiments can be carried out for all pertinent cytotoxic agents.  
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2.3 Production of Radioactive Gold (
198
Au) 
Production of Au-198 was carried out at the Texas A&M University Nuclear 
Science Center (NSC). Briefly, 10 mg of high-purity gold (III) chloride trihydrate 
(Sigma Aldrich, St. Louis, Mo) in solid form was irradiated at the NSC for a minimum 
period of 4 h. Neutron activation of 
197
Au resulted in the production of 
198
Au via the 
reaction 
197Au(n,γ)198Au. The thermal neutron cross-section is approximately 4916 
barns. The activated solid sample was transported from the NSC to our labs using a 
compact shipment system for radioactive material (Model 001-724, Biodex Medical 
Systems, Shirley, New York). Upon receipt of the sample, an HPGe detector (Canberra 
Industries, Meridian, CT) was used to assess the radioactive purity of 198-Au and the 
presence of potential radioactive impurities or contaminants in the sample. A dose 
calibrator (ATOMLAB 500 Dose Calibrator, Biodex Medical Systems, Shirley, NY) was 
used to assess the net activity of the radioactive sample. The activity levels of 
198
Au 
received varied considerably, depending on irradiation time at NSC and elapsed time for 
delivery.  
The radionuclide 
198
Au decays via beta particle emission and has a physical half-
life of 2.6947 days with an average beta particle energy is 0.311 MeV. Table 1 presents 
the particle emission and abundances (yields) from 
198
Au. 
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Table 1. Particle emissions and yields from the decay of 
198
Au. 
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2.4 Production of Radioactive Gold Nanoparticles (
198
Au-Nps)
Radioactive AuNPs were produced using the Turkevich method (29) as described 
by Kumar, et. al. (30) and Frens et. al. (31). Briefly, 1 mL of a 12.7 mM 
198
Au 
chloroauric acid solution was added to 49 mL of deionized ultra-filtered (DIUF) H2O in 
a clean 100 mL three-neck round-bottom flask fitted with a stir bar and reflux condenser. 
To this solution under reflux was added 0.94 mL of 38.8 mM trisodium citrate. The 
solution turned cherry red in ca. 2-3 min, after which refluxing was continued for 10 
min, producing 50 mL of highly spherical, mono-disperse gold nanoparticles between 15 
to 30 nm in diameter, depending on chloroauric acid concentration. Particles were 
characterized by transmission electron microscopy (TEM) and UV-Vis spectroscopy. 
Nanoparticle size may be altered by the timing of trisodium citrate addition to the flask 
(31). Nanoparticles were found to be stable for several months if stored at 4 °C. 
2.5 Nanoparticle Characterization Using NanoDrop 2000C Spectrophotometer 
Nanoparticles produced in our laboratory where compared with commercially 
available standards obtained from CytoDiagnostics, Inc. and came with a certificate for 
nanoparticle size and concentration. In order to find the size of the gold nanoparticles, 
each sample was measured using the Thermo Scientific NanoDrop 2000C 
spectrophotometer. From each sample, 1 mL was pipetted into the cuvette and measured 
to produce absorbance spectra as a function of wavelengths (Figure 3). The wavelength 
for each sample was compared to the standard and showed strong correlation; while the 
absorbance peaks were recorded for the calculation of the sample concentration. 
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Figure 3. UV-Vis absorbance as a function wavelength (nm) for different AuNP 
standards of 5, 10, 15, 20, 30, 40, 60, 80 and 100 nm in diameter obtained using a 
spectrophotometer (NanoDrop 2000C, Thermo Scientific, Inc.). 
 
 
 
The correlation between peak absorbance and nanoparticle size was plotted and fitted to 
a quadratic equation (Figure 4), where The relationship found was 𝐴 = 5.1602 × 102 +
1.1918 × 10−1𝐷 + 4.5615 × 10−3𝐷2 with a correlation coefficient of R = 0.99905. In 
this matter, it was possible to assess the average particle size from any of our 
experiments producing radioactive gold nanoparticles.  
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Figure 4. Absorbance peak as a function nanoparticle diameter obtained using different 
AuNP standards of 5, 10, 15, 20, 30, 40, 60, 80 and 100 nm.  
 
 
 
The concentration of gold nanoparticles was calculated using the Beer-Lambert 
law expressed as 
 𝐴 = 𝜀 ∙ 𝑏 ∙ 𝐶 (1) 
where ε represents the extinction coefficients M-1  cm-1( ), b that is the path length (cm), 
and C is the concentration in the sample expressed in molar concentration (M), and A is 
the absorbance peak. Previously, the extinction coefficients, ε, were determined by Liu 
et al, (32) using UV-Vis spectroscopy for different particle sizes and surface ligands.  In 
our case the surface ligand is trisodium citrate and the path length of our 
spectrophotometer is set at b = 1 cm.  The nanoparticle concentrations from our samples 
produced in our laboratory were calculated using Eq. (1).  The extinction coefficients as 
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a function of time estimated by Liu et al and those calculated using the standards showed 
high correlation as shown in Figures 5 and 6. 
Figure 5. Extinction coefficient,  as a function of nanoparticle diameter, d, estimated 
by Liu et al., (32) and those calculated using the standards supplied by CytoDiagnostics, 
Inc. The correlation between them is in good agreement.   
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Figure 6. Comparison between gold nanoparticle concentrations obtained from standards 
versus those calculated using the extinction coefficient, , given by the equation 
established from Liu et al., (32). The difference between our standards and those 
calculated was within range.  
 
 
 
2.6 Nanoparticle Characterization Using the NanoSight NS300 
The NanoSight NS300 instrument was also employed in the characterization of 
the nanoparticles. The system uses laser diffraction to assess the random Brownian 
motion or tracks of nanoparticles in a viscous fluid and based on the Stokes-Einstein law 
the particle diameter is estimated. Again, the CytoDiagnostics, Inc. standards and their 
associated certificate for nanoparticle size and concentration were utilized. From each 
sample, 10 µL was introduced into the system and measured to produce normalized 
concentration spectra as a function of nanoparticle diameter as shown in Figures 7 
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through 10. The data from the spectra were then analyzed to find the diameter size of the 
nanoparticles.  
The calculated diameter sizes were compared to the standards where they showed 
moderate correlation. The nanoparticles diameter sizes for the 10, 15, 30, and 60 nm 
nanoparticles were measured to be 6.6, 17.6, 34.8, and 64.4 nm respectively.  
There was a 34% difference for the 10 nm AuNP, 17.33 % difference for the     
15 nm AuNP, 16.0% difference for the 30 nm AuNP, and 7.33% difference for the 60 
nm AuNP.  
 
 
 
 
Figure 7. The average concentration as a function nanoparticle diameter (nm) for AuNP 
standard of 10 nm diameter obtained using the NanoSight NS300 instrument. 
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Figure 8. The average concentration as a function nanoparticle diameter (nm) for AuNP 
standard of 15 nm diameter obtained using the NanoSight NS300 instrument. 
 
 
   
 
Figure 9. The average concentration as a function nanoparticle diameter (nm) for AuNP 
standard of 30 nm diameter obtained using the NanoSight NS300 instrument. 
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Figure 10. The average concentration as a function nanoparticle diameter (nm) for AuNP 
standard of 60 nm diameter obtained using the NanoSight NS300 instrument. 
 
 
 
Using the data obtained from the NanoSight instrument, there was an observed 
inverse relationship between nanoparticle diameter and the error. This shows that the 
NanoSight instrument was not accurate for nanoparticles with a diameter smaller than 15 
nm; therefore, it will be difficult to differentiate between a small diameter nanoparticle 
and a group of the same diameter nanoparticles.  
 
2.7 TEM Image Analysis of AuNPs 
Transmission electron microscopy (TEM) was used to characterize the shape, 
size, and particle number of AuNP. Reproducible synthesis of AuNP was confirmed by 
TEM analysis. Figure 11 (Top) shows the TEM images of AuNPs at different 
magnifications, which show well defined nanoparticles with little to no nanoparticle 
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fusion. Image analysis for nanoparticle diameter was carried out using the software 
program ImageJ (33). A narrow distribution for AuNP was obtained with a range 
between 11.6 and 23.5 nm and an average diameter of 15.9 nm (Figure 11 (Bottom)) 
 
 
 
 
 
Figure 11. (Top) TEM images of AuNPs produced under the present method at different 
magnifications. (Bottom) Image analysis demonstrated a narrow particle size 
distribution, with a size range between 11.6 and 23.5 nm and an average diameter of 
15.9 nm. A lognormal distribution was fitted to the data showing the negative skew of 
the measured distribution towards larger size nanoparticles.   
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2.8 Estimation of Number of 
198
Au Radioactive Atoms Per Nanoparticle
Once radioactive NPs are generated using the Turkichev method, the total 
activity per unit volume (µCi/ml) was estimated using a dose calibrator (AtomLab 500, 
Biodex, Inc.). When a sample of solid chloroauric acid is activated, only a fraction of the 
197
Au gold atoms are transformed into 
198
Au. This reaction takes place via the
197Au(n,γ)198Au reaction. The fraction of atoms transformed into radioactive gold is very
small when compared to the total number of atoms of gold in the sample and it depends 
on neutron irradiation conditions, such as neutron flux (n cm
-2
 s
-1
), irradiation time, and
decay (e.g., due to delay in shipment). The nominal neutron flux used to irradiate our 
samples at the Nuclear Science Center was approximately 1×10
13
 n cm
-2
 s
-1
. The specific
activity of a radioactive sample is estimated using an HPGe detector. Specific activity is 
the total activity per unit mass of a compound; it is commonly expressed in MBq per mg. 
The number of radioactive gold per nanoparticle follows the Poisson distribution 
and depends on the average NP size and specific activity. For example, larger particles 
may contain more radioactive atoms and vice versa. The diameter distribution obtained 
from TEM images (Figure 11) was used to carry out these calculations and convoluted 
with Poisson distribution. The average activity (Bq) per nanoparticle, ANP, is the product 
of the NP mass multiplied by the specific activity, SA, where 
𝐴𝑁𝑃 = 𝑉𝑁𝑃 ∙ 𝜌 ∙ 𝑆𝐴 =
4
3
𝜋𝑟𝑁𝑃
3 ∙ 𝜌 ∙ 𝑆𝐴
(2) 
where rNP  is the radius of a nanoparticle. The average number of radioactive atoms per
nanoparticle,NNP, is then given by
29 
𝑁𝑁𝑃 =
𝐴𝑁𝑃
𝜆
(3) 
where λ = 2.98×10-6 s is the decay constant of 198Au . Thus the average number of
radioactive atoms increases with specific activity SA. The probability of number of 
radioactive atoms per NP with a specific radius is given by 
𝑃(𝑥) =
𝜇𝑥𝑒−𝑥
𝑥!
(4) 
Where 𝜇 = 𝑁𝑁𝑃  is the average number of radioactive atoms in a nanoparticle. Thus, the 
fraction of radioactive atoms as a function of SA for a nominal NP diameter of 15.9 is 
given in Figure 12. 
Once radioactive nanoparticles are produced, it is possible to assess the 
distribution of radioactive atoms per nanoparticle in a given solution using an estimate of 
the average diameter, nanoparticle concentration (NPs per milliliter), and activity 
concentration per unit volume of the sample. The average diameter can be calculated 
using the UV-Vis method; the concentration of NPs can be estimated using the optical 
absorption, and the activity concentration (not specific activity) using a dose calibrator.  
Therefore, we can write 
𝜇 =
1
𝜆(𝑠−1) 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝐴 (𝐵𝑞 𝑚𝑙−1)
𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝑁𝑃(𝑁𝑃𝑠 𝑚𝑙−1)
(5) 
and based on the Poisson distribution, the fraction of NPs with zero radioactivity atoms 
is given by 𝑃0) = e−𝜇, similar estimates can be made for one radioactive and multiple
radioactive atoms per nanoparticle. 
30 
Figure 12. Poisson distribution showing the fraction or probability of having zero, one or 
more radioactive atoms of 
198
Au per NP as a function of SA (MBq mg
-1
). The fraction of
NPs that will have a zero radioactive atoms decreases exponentially as a function of SA. 
The nominal NP diameter used in these calculations was 15.9 nm.  
These calculations are required in order to assess how many radioactive atoms 
and corresponding decays will occur per NP. Each radioactive decay will emit certain 
characteristic radiative emissions based on the decay scheme of 
198
Au. For a given NP,
each radiative emission will occur in the same cell when the nanoparticle is entrapped in 
the cell surface or internalized in the cytoplasm, yielding a higher dose per tumor cell. 
2.9 Pharmacokinetics and Dosimetry at the Cellular Level of 
198
Au-NP HIV-1 Tat
The dosimetry of a single 
198
Au-NP requires the use of the radiative emissions of
198
Au.  The radionuclide 
198
Au is a pure beta-particle emitter with multiple characteristic
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gamma and x-ray emissions. The average energy of the emitted beta particles is 0.311 
MeV with a maximum energy of 1.37 MeV (see Figure 13).  The average range of these 
electrons in water was estimated at 0.099 cm, which is smaller than the size of a single 
well. There are also discrete electrons and x-ray emissions with significant intensities 
that contribute to the localized absorbed dose per radioactive decay.  
 
 
 
Figure 13. Probability density function (pdf) of the energy of beta particles emitted by 
the decay of 
198
Au, and percent intensity of discrete x-ray and electron emissions. The 
energy of the emitted beta particle is sampled from this distribution. 
 
 
   
The pharmacokinetic equations that govern the present system of cell growth are 
complex. We did not attempt to assess the absorbed dose to a single cell as the system is 
under continuous growth and requires a complex system of differential equations where 
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that radiation dosimetry of the present system as a bolus is not proper, as cell cycle 
continues to plays significant role and the distribution of radioactive nanoparticles that 
may not be homogenous among cells. Thus, the cumulative activity in the cell system 
will be based on cell growth, and internal nanoparticle micro-distribution among cells. 
 
2.10 PEG Modification of 
198
AuNPs 
PEG (polyethylene glycol) modification, or PEGylation, is one of the most 
commonly used surface modification methods for gold nanoparticles. The PEG coating 
decreases the reduction of protein absorption and increases the stability of the AuNPs. 
The PEG modification was carried out in our laboratory using the methods described by 
Cytodiagnostic (Tech Note #105). Briefly, 1 mL (0.25 nmol) of AuNPs coated with 
citrate (1.5x1014 particles/mL) was PEGylated by simple ligand exchange of citrate with 
a 1000-fold molar excess of carboxy-PEG5000-thiol (CM-PEG500-SH, Laysan Bio) in 
DI water for 15 min. PEGylated carboxyl-terminal AuNPs (198AuNP-PEG-COOH) 
were collected by centrifugal filtration at 5000 x g using 10 kDa MWCO Amicon Ultra-
15 centrifugal filter units (Millipore) to remove excess unreacted PEG reagents, 
repeatedly washed with DI water, and reconstituted in 0.5 mL MES buffer for 
immunoconjugation. 
 
2.11 Functionalization Cell Penetration Peptide 
Functionalization with the cell penetrating peptide of PEGylated radioactive gold 
nanoparticles was carried out using the method described by Cytodiagnostic             
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(Tech Note #105)
i
. Briefly, 30 mg of 1-Ethyl-3-carbodiimide hydrochloride (EDC) 
(Sigma, Cat# E1769) and 36 mg of N- hydroxysulfosuccinimide (Sufo-NHS) (Sigma, 
Cat# 56485) was mixed in 1 mL of MES buffer (Sigma, Cat# M5287) to form the 
EDC/NHS solution. Conde et al., has described in detail the above functionalization 
method. The advantage of EDC coupling in the increase in water solubility of PEG-
AuNPs, which allows for direct bio-conjugation without the prior use of an organic 
solvent to increase the stability of an active ester, such as N-hydroxysulfoxuccinimide 
(sulfo-NHS).  The addition of sulfo-NHS stabilizes the amine-reactive intermediate by 
converting it to an amine-reactive sulfo-NHS ester; therefore, it increases the efficiency 
of EDC-mediated coupling reactions (34). The following steps were followed: 
1. We prepared a fresh EDC/NHS mix solution, as described before, in MES buffer 
at a concentration of 30 mg/mL and 36 mg/mL, respectively.  
2. We used 10-µL of PEGylated radioactive AuNPs and mixed with 10 µL of the 
EDC/NHS solution.  
3. The new solution was then incubated for 30 minutes under room temperature.   
4. We added 1 mL of PBS Tween (PBST) and vortex thoroughly.  
5. The solution was centrifuged at 6,500 g for 30 min. 
6. The supernatant was removed. 
7. Added 10 μL of HIV-1 Tat (1 mg/mL in 1X PBS) 
8. Sonicated in a water bath sonicator for 10 sec. 
                                                 
i
 http://www.cytodiagnostics.com/pdf/Covalent-conjugation-carboxyl-gold-
nanoparticles-TECH_NOTE_105.pdf 
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9. Incubated for 2 to 4 hours at room temperature with mixing.  
10. Added 1 mL of PBST and vortex thoroughly.  
11. Spin down by centrifugation at 3,500 g for 30 min.  
12. Removed most of the supernatant.  
13. Added 50 μL PBS with 1% BSA.  
14. Stored at 4 degrees until ready to use.  
 
Once radioactive and non-radioactive AuNP are functionalized with HIV-1 Tat, they are 
ready to be used accordingly based on the arrangement described with RTCA system.   
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3. RESULTS 
 
3.1 SKBr-3 RTCA Cell Seeding Experiments 
In order to carry out our experiments with good growth of SKBr-3 over a period 
of time that is acceptable for observation without the need to change the growth medium, 
we carried out a cell seeding experiment. The RTCA system was used to assess the 
optimal seeding per well of SKBr-3 cells. Seeding densities were carried out at 3300, 
5500, 10000, and 25000 cells per well. Figure 14 illustrates the cell index (CI) response 
as a function of time for a period of more than 190 h. The maximum CI achieved by 
these cells was estimated at 3.0 without exchanging the cell growth media.  
 
 
 
Figure 14. RTCA cell Index (CI) response as a function of time for seeding per well of 
3,300 (pink), 5,000 (blue), 10,000 (green) and 25,000 (red) per well. The optimal 
seeding was determined at 10,000 cells per well within a time lapse of less than 196 h. 
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Based on these data, the optimal seeding was estimated at around 10,000 cells 
per well, reaching a CI of 1.5 within 84 h and allowing the assessment of potential 
cytotoxic response for CI < 1.5 or re-growth response for CI > 1.5. Based on these 
results, future experiments were carried out at a seeding of 10,000 cells per well. 
3.2 Cytotoxicity of Doxorubicin on SKBr-3 
For the purpose of evaluation and further comparison, the response of SKBr-3 to 
the chemotherapy drug doxorubicin was evaluated using the RTCA system. The 
mechanism of action of Doxil is by intercalating and inhibiting biosynthesis of 
topoisomerase II, which disrupts DNA synthesis. 
We seeded 10,000 cells per well and allowed to them to grow for a period of 24 
hours. Quadruplicates were used for each concentration and controls. The resulting 
RTCA response was dose dependent, as shown in Figure 15 where higher molar 
concentrations induced a rapid proliferation rate (higher CI) with a subsequent drop, 
which reveals that tumors cells continue to reproduce and grow after exposure. 
However, after several cell cycles cell death is inevitable via apoptosis, necrosis, 
autophagy, or mitotic catastrophe. The time required to achieve the same cell index 
(cross over) of controls for each molar concentration is shown in Figure 16, which 
indicates the inverse relationship between growth time reduction and molar 
concentration. This expression is similar to the dose-effect relationship laws used by 
different pharmacokinetic groups relation effect versus dose; however, in here time is 
used as a variable to assess the required time to inhibit continuous growth (35). 
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Figure 15. Cell index (CI) as a function of time for SKBr-3 cells exposed to different 
molar concentrations of doxorubicin.  The molar concentrations were 2.2 µM (red), 1.10 
µM (green), 0.55 µM (Pink), and controls (Blue). The solid black line represents the 
point at which the CI is normalized to unity when doxorubicin was given to the cells. 
 
 
 
 
Figure 16. Time required achieving the same CI end-point (cross over) as a function of 
doxorubicin molar concentration.  
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3.3 Cytotoxicity of 2-Gy X-rays 
The cytotoxic response to an absorbed dose of 2 Gy from photons (SF2Gy) is 
commonly used as a reference dose when comparing other therapies or cytotoxic 
modalities such as chemotherapy and radioimmunotherapy in vitro. Experiments were 
carried out using the RTCA system using two plates. Initially 10,000 cells per well were 
seeded and were allowed to grow for a period of 24 h. At the end of 24 h, one plate was 
irradiated with a total dose of 2 Gy while the other was used as a control.  Figure 17 
presents the CI response as a function of time. The CI was normalized at the time of 
irradiation (black reference line). We observed that SKBr-3 had an over-response, i.e., a 
fast cell growth response, immediately after irradiation that lasted less than 24 h, reached 
a peak, and then declined to the same levels as controls due to cell death; possibly 
apoptosis. Growth media was replaced twice after irradiation. The observable effects of 
irradiation were seen after 147 h, where the CI for irradiated versus control differed 
significantly, by a factor of 3. These results demonstrate that cell death is not quite 
immediate after irradiation and that there are significant cell growth kinetic changes after 
irradiation, leading to a fast growth response followed by cell death only 60 h or more 
after irradiation. 
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Figure 17. Normalized CI as a function of time for SKBr-3 cells exposed to 2 Gy (red 
line) and controls (blue line). The solid black line represents the point at which the CI is 
normalized to unity at the time of irradiation.  
 
 
 
It was not clear if these results can be modeled using the Gompertz equation for 
cellular growth (36). What is of interest is the quasi-stable response of SKBr-3 for more 
than 50 h after irradiation, which indicates the death of multiple groups of cells at 
different times and rates. This may be due to the fact that cells are not synchronous (in 
different cell cycle phases) at the time of irradiation – because cells in the G2/M phase 
(undergoing DNA synthesis) are likely to be more radiosensitive that those in the S/G1 
phase. When compared to the RTCA response of x-rays to that of doxorubicin, we 
observe similarities in cell proliferation immediate after exposure of the cytotoxic agent. 
However, for 2-Gy x-rays the time required to obtain a therapeutic response was more 
than 120 hours after exposure. In contrast, doxorubicin had a shorter therapeutic effect 
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after as a function of concentration.  The obtained CI results were used to compare the 
cytotoxicity of doxorubicin, and functionalized 
198
AuNP-HIV-1 Tat to SKBr-3 cells. 
 
3.4 Characterization of 
198
AuNPs 
In order to characterize the produced radioactive gold nanoparticles, 1 ml of the 
resulting solution was used to assess the surface plasmon resonance using the NanoDrop 
2000C spectrophotometer. Figure 18 shows the UV-Vis spectrum as a function of 
photon wavelength.  
 
 
 
Figure 18. UV-Vis spectrum of radioactive gold nanoparticles produced for the present 
experiments. The surface plasmon resonance (maximum peak) was observed at 525 nm 
with an absorbance of 1.341 corresponding to a gold nanoparticle diameter of 32.9 nm 
and a concentration of 2.29×10
11
 NP/ml. 
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The absorbance peak was measured at 525 nm, which corresponded to particle 
size of 32.9 nm. The measured absorbance peak at 525 nm was 1.34 resulting in a 
concentration of 2.29×10
11
 (NP/ml). Using the dose calibrator, the measured activity of 
the 1 ml sample was 480 (µCi/ml). The estimated number of 
198
Au atoms per 
nanoparticle was 25.9, which resulted in a negligible zero-fraction P X = 0( ) = e-25.9( ).  
 
3.5 Cytotoxicity of 
198
AuNPs and 
198
AuNPs-HIV-1 Tat 
 The cytotoxicity of radioactive 
198
AuNPs was assessed using the RTCA system 
to corroborate its innocuous effect on SKBr-3. We seeded 10500 tumor cells per well 
and after 30 hours of incubation, HIV1-Tat functionalized and non-functionalized 
198
AuNP with different activities were added into the wells in quadruplicates. The 
activities used were 50, 100, 500, 1000, and 1500 kBq. The experimental arrangement 
was as follow: 
1. SKBr-3 cells used as a control 
2. SKBr-3 cells treated with AuNPs (non-radioactive) 
3. SKBr-3 cells treated with AuNP HIV-1 Tat (non-radioactive) 
4. SKBr-3 cells treated with 198AuNPs 
5. SKBr-3 cells treated with 198AuNP HIV-1 Tat  
 
Figures 19 through 22 present the cell growth response as a function of time for 
the different experimental arrangements as described above. The incubation period was 
for 12 hours and after that the medium was exchanged and cells were washed once to 
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remove any non-internalized nanoparticles. However, it is important to mention that we 
were not able to determine the fraction of activity that was retained in the wells after 
washing them with PBS. We expected that internalization of 
198
AuNPs-HIV-1 Tat will 
have a significant impact in cell growth; however, as observed in Figure 22, the growth 
profile of 
198
AuNPs and 
198
AuNPS-HIV-1 Tat was similar with a minimal reduction in 
cell index (CI) by those treated with 
198
AuNPS-HIV-1 Tat. In here we question the 
effective internalization of 
198
AuNPS-HIV-1 Tat and further studies are required to 
assess if internalization was 1) limited by nanoparticle size, 2) by number of HIV-1 Tat 
CPP per nanoparticle, 3) by radiation effects on cell cycle, or 4) lack of directionality of 
the HIV-1 Tat CPP against the cell surface. Nonetheless, we were able to observe a 
slight gain in cytotoxicity by the 
198
AuNPs-HIV-1 Tat when compared with 
198
AuNPs 
alone.  The cell response to non-radioactive
 
AuNPs-HIV-1 Tat was similar to that of 
controls as shown in Figure 19; this indicates that the non-radioactive
 
AuNPs-HIV-1 Tat 
had no effect on the SKBr-3 cells growth.  
In terms of activity, the cell growth response to 50, 100, and 500 kBq of 
198
AuNPs and 
198
AuNPs-HIV-1 Tat was not significant as shown in Figure 20 and 21; 
the cell growth response was similar to controls. However, the cell growth response to 
1000 and 1500 kBq of 
198
AuNPs and 
198
AuNPs-HIV-1 Tat was observed distinctly. This 
shows that doses bellow 1000 kBq were too low to yield a cellular growth response.    
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Figure 19. Normalized Cell Index as a function of time for SKBr-3 cells exposed to 
nonradioactive AuNP (green line) and control (red line). The solid black lines represent 
the incubation time between the addition of the AuNP and the time when the medium 
was replaced. 
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Figure 20. Normalized Cell Index as a function of time for SKBr-3 cells exposed to 
198
AuNPs-HIV-1 Tat with an activity of 50 kBq (green line) and 100 kBq (blue line), 
198
AuNPs with an activity of 50 kBq (pink line) and 100 kBq (brown line), and control 
(red line). The solid black lines represent the incubation time between the addition of the 
AuNP and the time when the medium was replaced. 
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Figure 21. Normalized Cell Index as a function of time for SKBr-3 cells exposed to 
198
AuNPs-HIV-1 Tat (green line) and 
198
AuNPs (blue line) with an activity of 500 kBq
and control (red line). The solid black lines represent the incubation time between the 
addition of the AuNP and the time when the medium was replaced. 
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Figure 22. Normalized Cell Index as a function of time for SKBr-3 cells exposed to 
198
AuNPs-HIV-1 Tat with an activity of 1000 kBq (green line) and 1500 kBq (blue line), 
198
AuNPs with an activity of 1000 kBq (pink line) and 1500 kBq (brown line), and 
control (red line). The solid black lines represent the incubation time between the 
addition of the AuNP and the time when the medium was replaced. 
 
 
The cell response to 
198
AuNPs-HIV-1 Tat and 
198
AuNPs with activities of 1000 
and 1500 kBq was initially observed in the slope of the spectrum. Following the 
exchange of the medium inside the wells, a decrease in the slope was observed. This 
showed that the cells duplication rate was slowed as a function of time.  The major 
observable effects of radioactive AuNP were seen after 150 h (~ 6 d), where the trend of 
the treated cells started declining with a very fast rate in cell death afterwards, while the 
trend of the controls kept growing reaching a plateau at 175 h (~ 7 d).  
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4. DISCUSSIONS 
 
The biological functionalization of nanoparticles is an area of extensive research 
(37). The use of passive or active strategies for targeting tumors depends on the 
spatiotemporal pathophysiology of the tumor and the competitive processes embedded in 
the interaction and obstacles encountered by the nanoparticle/nanotherapeutic within the 
microenvironment of normal and tumor tissues. When delivering radioactive payloads, 
the design of a carrier will be based on the pathophysiology of the tumor itself. Passive 
strategies based on the enhanced permeability and retention effect (EPR) of tumors have 
been widely used with relative success in the treatment of prostate cancer using animal 
models (38). However, active strategies using immuno-conjugated monoclonal 
antibodies and their fragments, and tumor-directed cell penetrating peptides (39-43) are 
therapeutically more significant. This is because the EPR effect in small tumors is 
minimal or non-existent, which is the case for minimal residual disease and microscopic 
metastatic cancer. Therefore, preemptive active targeting strategies must be developed 
and studied to attack a tumor at its early stage of development before it becomes 
intractable, as is the case when tumors are radiographically observable.  
In the present study we accomplished the production of 
198
AuNPs using a 
modified Turkevich method and corroborated the NP size using TEM and UV-Vis. We 
assessed the cytotoxicity of x-rays for an absorbed dose of 2-Gy, which resulted in a 
very peculiar growth response as a function of time. What is of interest is the immediate 
growth response after irradiation, which is attributed to a morphological response by 
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increasing the cell surface attachment reaching a plateau and subsequent cell death, 
which was similar to controls for a period of approximately 24 hours. Subsequent to this 
time, the effect of irradiation becomes noticeable showing a decrease in cell index (CI) 
by a factor of 2.3 at 150 hours after irradiation between irradiated and controls. 
However, the rates (slopes) of cell death of irradiated and controls were almost identical. 
These results indicate that further research is required to assess if this effect is consistent 
and reproducible at higher absorbed doses (4 Gy and up). Nonetheless, the cytotoxicity 
of 2-Gy x-ray was obtained for further comparison with functionalized and non-
functionalized 
198
AuNPs.  
We also assessed the cytotoxicity of the chemotherapy agent doxorubicin. Using 
the same SKBr-3 seeding of 10,000 cells per well and the same RTCA system settings at 
different molar concentrations.  The immediate tumor growth response as a function of 
molar concentration was similar to that of 2-Gy x-ray irradiation. We observe a fast 
growth response for a short period of time with a subsequent decline by cell death; 
however, unlike the plateau response observed in x-rays, cell death continued and the CI 
declined in an exponential form as a function of time.  This demonstrates that the 
mechanism of action and cell death pathways between ionizing radiation and 
chemotherapy may be completely different. It is clear that in both cases apoptosis may 
be the mechanism for cell death; however, cell death may be reached via different 
pathways that are completely unrelated by mechanism of action or activation of 
caspases, which can be either intrinsic (mitochondria mediated) or extrinsic (death 
receptor mediated). It is important also to point out that a 2-Gy absorbed dose was 
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delivered in a single dose providing a single event or insult to the SKBr-3 cell culture; 
on the other hand, doxorubicin was constantly present in the growth media of the SKBr-
3 cell culture. This difference may account for observing the plateau response after 
immediate cell growth and cell death. It is important to mention that, in pharmacokinetic 
terms, radioactive 
198
AuNP is a form of protracted irradiation similar to that
chemotherapy agent but utilizes radiation (ionizing radiation, beta particles and photons) 
as a cytotoxic agent. 
Furthermore, using the RTCA system found that bare non-radioactive AuNPs 
have negligible or no cytotoxicity on SKBr-3 cells.  We used a very high concentration 
of AuNPs in these experiments and noticed no statistical difference in cell growth among 
the different well cultures and controls. This is of course an in vitro study using cell 
culture conditions; however, AuNPs may elicit a cytotoxic response under different 
growth conditions in vivo. 
We also estimated the distribution of radioactive atoms per AuNP. The analysis 
required the calculation of the specific activity (SA), which was used to calculate the 
average number of radioactive 
198
Au atoms per NP; we used the Poisson distribution to
assess the fraction of NPs that will have zero, one, two, three, etc. radioactive atoms. 
This is important in the preparation of radioactive gold NPs. A very low SA will result in 
a large fraction of AuNPs containing no radioactive 
198
Au atoms, whereas a high SA will
results in a very optimal capacity of cell-kill as multiple radioactive decays at the same 
site within a tumor cell (either cell surface or cytoplasm) will occur yielding significant 
localized damage to the tumor cell. 
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The dosimetry of 
198
AuNPs is extremely complex requiring the use of Monte
Carlo transport methods for electrons and photons using a cellular phantom that mimics 
the internal components of a cell, including its membrane, cytoplasm, nucleus, including 
and cell replication. However, we presented the basis for the dosimetry of 
198
AuNPs by
organizing the corresponding radiative emissions (beta particles and characteristic 
electrons and x-rays) and probability distributions per decay (Bq-s) that need to be 
considered in these dosimetric calculations.  However, we did not estimate the dose to 
the system an individual cell, as the system is very complex. A therapeutic effect was 
observed at 1000, and 1500 kBq per well but lower doses may be indicative of high 
radio-resistant of SKBr-3 cells. 
In summary, results from the present study suggest that the effect of radioactive 
nanoparticles may be used as a potential strategy for the treatment of metastatic cancer 
based on the fact that a small response was observed at 1000, and 1500 kBq. If the 
pharmacokinetics of the present entity is optimal with a long residence time in blood, it 
may represent a potential opportunity to carry out chronic administrations of the present 
radiotherapeutic nanoparticle, yielding a management approach of metastatic cancer. 
Thus, further in vitro and in vivo investigations are warranted. 
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5. CONCLUSIONS
Novel potential cancer treatments can be attained by the synthesis of targeted 
radionuclide therapy (TRT) and nuclear nanotechnology. The use of nuclear 
nanotechnologies as a new paradigm where nanoparticle cores can serve as super-
carriers of radionuclides may potentially yielding new endo-radiotherapy agents with 
potentially higher safety and efficacy profile than those currently used clinically. The use 
of nanoparticles as carriers of a therapeutic load was possible using gold-on-gold (
198
Au-
197
Au). Our method yielded good mono-dispersed AuNPs with an average diameter of 
32.9 nm. We targeted tumor cells using the HIV-1 Tat cell penetrating peptide as an 
initial proof of principle. The cell growth results showed a clear dependence on 
administered activity and that cell growth response was only observable at 1000 and 
1500 kBq per well for both functionalized and non-functionalized 
198
AuNP. Even though
an observable and distinct higher cytotoxic response was observed for those cells treated 
with 
198
AuNP-HIV-1 Tat.
In summary, the use of 
198
Au is a first step and it was used as a surrogate for
other radionuclides. For future work, we propose to use nano-alloys as diagnostic and 
therapeutic agent such as the alpha particle emitting radionuclide, 
211
At, for the treatment
of metastatic cancer. Moreover, we propose the strategy of 
68
Ga-AuNPs HIV1-Tat for
PET diagnosis. The positron emitting radionuclide 
68
Ga can be obtained using a
68
Ge/
68
Ga generator.
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